Latest Breaking News On - Keith blundy - Page 1 : comparemela.com

PharmEnable Closes $7 5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases

PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture .

United kingdomSosei heptaresKeith blundyJeffrey mooreChristine martinJonathan milnerUniversity of cambridge enterprise fundCancer research technology ltdKudos pharmaceuticals ltdUniversity of cambridgeParkwalk advisors heyfordInivata ltdMission therapeuticsMillennium pharmaceuticalsMitsubishi tanabe pharma groupCancer research united kingdom

PharmEnable Closes $7 5M Pre-Series Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United kingdomJonathan milnerChristine martinSosei heptaresKeith blundyJeffrey mooreUniversity of cambridgeUniversity of cambridge enterprise fundMitsubishi tanabe pharma groupUnited kingdom basedVenture managementCambridge enterpriseCambridge enterprise fundParkwalk advisorsHeyford trustMartlet capital

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform ALAMEDA, Calif. and CAMBRIDGE, England,

United kingdomTony kouzaridesKeith blundyEric miskaPeter lambPrnewswire exelixis incTaiho venturesExchange commissionUniversity of cambridgeExelixis incIp groupSeroba life sciencesExecutive vice presidentScientific strategyChief scientific officerChief executive officer

Exelixis, Inc : Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform - Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics

United kingdomTony kouzaridesEva haasVarant shirvanianHal mackinsKeith blundyMary clarkEric miskaElakiya rangarajahPeter lambDaiichi sankyo companyTaiho venturesExchange commissionUniversity of cambridgeExelixis incStrategic communications

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes | More News

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes | More News
pipelinereview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pipelinereview.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomTony kouzaridesKeith blundyEric miskaPeter lambExelixis inc on facebookI exelixis incTaiho venturesUniversity of cambridgeExelixis incIp groupSeroba life sciencesExclusive collaborationLicense agreementDevelop inhibitors